We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Dipstick Assay Evaluated for Liver Fluke Diagnosis

By LabMedica International staff writers
Posted on 22 May 2012
A dipstick assay has been developed to diagnose fascioliasis, and its diagnostic efficacy evaluated in comparison to an immunoassay.

The dipstick uses excretory–secretory antigen from Fasciola gigantica dotted onto nitrocellulose paper using a sheet Mini-Protean II multiscreen apparatus to which human serum is applied. More...


Parasitologists at Ain Shams University (Cairo, Egypt) collected blood samples were collected from 60 individuals categorized into three groups. Group I consisted of 30 fascioliasis patients, diagnosed by detection of eggs of Fasciola in the stool and serologically by positive indirect hemagglutination test. Group II consisted of 20 patients with other parasitic diseases, and Group III consisted of 20 healthy individuals proven negative for fascioliasis and other parasitic diseases.

The enzyme linked immunosorbent assay (ELISA) was carried using a standard protocol and the absorbance was measured at 450 nm using a microplate reader. Samples were considered positive if their optical density was greater than the mean of healthy control samples plus three standard deviations. On the dipstick, a dark purple to brown band indicated a positive reaction.

The dipsticks' accuracy was 98.3%, with a sensitivity of 100%, a specificity of 96.7%, and negative predictive value of 100%. The sensitivity, specificity, and diagnostic accuracy of the ELISA were 100%, 96.7%, and 98.3%, respectively. The nitrocellulose paper and sheet Mini-Protean II multiscreen apparatus are both products of Bio-Rad (Hercules, CA, USA).

The authors concluded that the dipstick is a simple antigen and serum-conservative test requires only micrograms of parasite antigen and 20 µL of patient's sera. This test can be carried out while the patients wait, and would be more practical than what is currently done especially in rural areas and district hospitals. The test has its merit in being both qualitative, able to screen large numbers of blood samples, and quantitative assay, as the end-point titration of individual's sera can be determined. It is estimated that over 2.4 million people are infected with Fasciola species worldwide and around 91 million are at risk of infection. The study was published in the May 2012 issue of the journal Parasitology Research.

Related Links:
Ain Shams University
Bio-Rad



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.